Related Experiment Video
Updated: Jun 1, 2026
09:13
Understanding the Development of Compensatory Pathways in a Mutant Malaria Parasite Harbouring Hypomorphic Allele of Plant-Like Kinases
Published on: November 22, 2024
Non-PKU mild hyperphenylalaninemia (MHP)--the dilemma
1Division of Clinical Genetics, Department of Paediatrics, The Hospital for Sick Children, 555 University Ave, Toronto, ON, M5G 1X8, Canada. whanley@pathcom.com
Molecular Genetics and Metabolism
|June 3, 2011
Summary
Mild hyperphenylalaninemia (MHP) patients may not benefit from treatments like tetrahydrobiopterin (BH4) or low phenylalanine diets. Current evidence does not support treating MHP, unlike phenylketonuria (PKU).
Area of Science:
- Metabolic Disorders
- Neurodevelopmental Disorders
- Genetics
Background:
- Recent reviews suggest potential neuropsychological deficits in non-PKU mild hyperphenylalaninemia (MHP) patients, prompting consideration for treatments like tetrahydrobiopterin (BH4) or low phenylalanine (Phe) diets.
- Phenylketonuria (PKU) patients, including Classical and Mild/Atypical variants, typically require mean lifetime Phe levels of 120-360 μmol/L for optimal outcomes.
- MHP patients naturally exhibit Phe levels between 200-600 μmol/L, a condition previously considered benign.
Purpose of the Study:
- To critically review the available literature regarding the potential benefits of treating MHP patients.
- To evaluate the evidence supporting neuropsychological benefits of BH4 and/or Phe-restricted diets in MHP.
- To advocate for a unified global classification system for PKU phenotypes.
Main Methods:
- Comprehensive literature review of existing studies on MHP and PKU.
- Analysis of Phe levels and treatment outcomes in PKU and MHP patient populations.
- Assessment of evidence for executive function deficits in MHP.
Main Results:
- The literature review uncovered no substantial evidence to support the treatment of MHP with BH4 or Phe-restricted diets.
- Optimal Phe levels for PKU management differ significantly from natural Phe levels observed in MHP.
- The benign nature of MHP requires further investigation with more subject testing.
Conclusions:
- Current evidence does not support the therapeutic intervention for MHP, contrasting with PKU management strategies.
- Further research and testing in MHP subjects are necessary to confirm these findings.
- A standardized international classification for PKU phenotypes is needed.
Related Concept Videos
01:20Inborn Errors of Metabolism
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
01:21Overview of Protein Metabolism
Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
01:21Huntington Disease l: Introduction
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
02:41Lethal Alleles
Agouti: A Lethal Allele
Lucien Cuénot discovered lethal alleles in 1905 while studying the inheritance of coat color in mice. The agouti gene is responsible for the color of the coat in mice. This gene codes for an agouti-signaling protein, which is responsible for melanin distribution in mammals. The wild-type allele gives rise to gray-brown coat color in mice, while the mutant allele gives rise to yellow coat color. In addition to coat color, the agouti gene is associated with the yellow...
Lucien Cuénot discovered lethal alleles in 1905 while studying the inheritance of coat color in mice. The agouti gene is responsible for the color of the coat in mice. This gene codes for an agouti-signaling protein, which is responsible for melanin distribution in mammals. The wild-type allele gives rise to gray-brown coat color in mice, while the mutant allele gives rise to yellow coat color. In addition to coat color, the agouti gene is associated with the yellow...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...